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ABSTRACT 
Background: Treatment of invasive aspergillosis is frequently 
unsuccessful, so innovations in therapy are needed. Clinical 
studies demonstrate that itraconazole may be an effective alter- 
native to amphotericin 6. ltraconezole also has been combined 
with amphotericin B in animal models of aspergillosis, but this 
regimen produced antagonistic effects. 
Objectives: To determine the role of itraconezole in the adjunc- 
tive treatment of invasive aspergillosis. 
Methods: A review was conducted of all patients with definite 
or probable aspergillosis from January 1995 to December 1997 
who were treated with conventional amphotericin B alone or in 
combination with itraconazole. 
Results: Of 21 patients, 10 received amphotericin B and 11 
received the combination. The two groups of patients were 
comparable clinically at baseline (including similar mean 
APACHE Ill scores). Both groups received similar doses and 
days of amphotericin B treatment. Of the patients who received 
combination therapy, nine (82%) were cured or improved, and 
of those who received only amphotericin B, five (50%) were 
cured or improved. 
Conclusions: This study demonstrates that itraconazole and 
amphotericin B given together are not clinically antagonistic and 
that the promise of combination therapy for aspergillosis should 
be evaluated further in a randomized clinical trial. 
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The risk for invasive aspergillosis is substantial among 
bone marrow transplant recipients, patients experiencing 
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prolonged granulocytopenia due to intensive cytotoxic 
chemotherapy, and those with severe immunosuppres- 
sion due to corticosteroids or human immunodeficiency 
virus (HIV) infection. lz2 As these populations grow in 
number and as more potent cytotoxic regimens are 
administered, the incidence of aspergillosis also is 
expected to increase. For example, Wald et al recently 
reported that the incidence of invasive aspergillosis 
among bone marrow transplant recipients at their center 
increased from 5.7% in 1987 to 11.2% in 1993.3 
Although early empirical treatment with high doses 
of amphotericin B (1.0-1.5 mg/kg/d) may improve 
survival among some patients with pulmonary aspergillo- 
sis,* the mortality from this infection remains unaccept- 
ably high. Mortality among patients with cerebral or 
pulmonary aspergillosis following allogeneic bone mar- 
row transplantation has been reported to exceed 95%.5,6 
In a review of more than 2000 cases of aspergillosis, the 
overall response to therapy was only 30 to 35%, although 
this improved to 55% for patients who were able to tol- 
erate at least 14 days of amphotericin B.’ 
Itraconazole is a broad-spectrum triazole antifungal 
agent that is available as a capsule or oral suspension. Its 
safety profile and therapeutic index are superior to those 
of amphotericin B. Itraconazole has fungicidal activity 
against Aspergillus species in vitro’; as a single agent in 
the treatment of invasive aspergillosis, it is effective in 
some patients.*s9 
The efficacy and safety of combination or adjuvant 
therapy of aspergillosis have not been determined.6 Stud- 
ies in animal models yield conflicting results: ampho- 
tericin B and flucytosine have been observed to be 
synergistic or indifferentlosll; amphotericin B and rifampin 
were synergistic in animal and in vitro studieslo but in a 
study from the Memorial Sloan-Kettering Cancer Center, 
patients given combinations of amphotericin B and 
rifampin received no therapeutic benefit and experienced 
an increased risk of skin eruptions compared with 
patients treated with only amphotericin B.12 Antagonism 
has been demonstrated with combined use of ampho- 
tericin B and ketoconazole,“z13 and finally, amphotericin 
B and itraconazole have produced indifference or antag- 
onism in animal models of aspergillosis.“J* 
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In an effort to determine the clinical effect of itra- 
conazole in combination with amphotericin B, a retro- 
spective study of patients with invasive aspergillosis was 
undertaken. 
METHODS 
Patients at Memorial Sloan-Kettering Cancer Center, a 434 
bed tertiary care cancer center in New York City, were 
identified through medical records and microbiology data- 
bases covering the period from January 1995 to Decem- 
ber 1997. Information obtained from the pharmacy 
database identified all patients who received ampho- 
tericin B alone or in combination with itraconazole. 
Patients who received lipid formulations of amphotericin 
B were excluded. 
Only patients with definite or probable aspergillosis 
were included. Definite aspergillosis was defined as (a) 
tissue histopathology showing acute branching septate 
hyphae with or without isolation of Aspergillus species 
from the same site or (b) isolation of Aspergillus species 
from an otherwise sterile tissue or body fluid obtained 
by an invasive diagnostic procedure, such as transbronchial 
biopsy or percutaneous or fine needle aspiration.15 Prob- 
able aspergillosis was defined as (a) neutropenic patients 
undergoing allogeneic bone marrow transplantation or 
peripheral stem-cell transplant or with a diagnosis of 
hematologic malignancy, aplastic anemia, or myelodys- 
plastic disorder who developed a positive bronchoalveo- 
lar lavage or sputum specimen for Aspergillus with no 
other clinically significant pulmonary pathogen identified 
and a compatible radiologic picture or (b) patients with 
HIV disease or acquired immunodeficiency syndrome 
(AIDS) with new infiltrates or nodules on chest x-ray or 
chest computed tomography (CT) and a bronchoalveolar 
lavage positive for Aspergillus and no other clinically sig- 
nificant pulmonary pathogen. Patients with aspergilloma 
or allergic bronchopulmonary aspergillosis were excluded. 
Baseline and follow-up clinical, radiologic, histopatho- 
logic, and mycologic data, as well as medication history 
were collected through May 1998. Baseline APACHE III 
score (an assessment of severity of illness and prediction 
of outcome) was calculated for each patient.16 
Patients were classified into two groups: (1) patients 
who received only amphotericin B during their entire 
episode of aspergillosis and (2) patients who received 
amphotericin B and itraconazole (400 mg/day) as follows: 
(a) amphotericin B and itraconazole simultaneously 
throughout the duration of treatment or (b) amphotericin 
B followed by amphotericin B and itraconazole and then 
itraconazole to complete therapy No patients were given 
itraconazoie alone at the initiation of treatment (Figure 
1). For patients tiho received combination therapy, the 
choice and timing for use of itraconazole appeared to be 
dependent on (1) the ability of the patient to take 
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Figure 1. Treatment regimens for patients who received amphotericin 
B and itraconazole. 
medication orally, (2) the severity of the patient’s medical 
status, (3) concerns about amphotericin B intolerance, 
and (4) the preference of the primary attending physi- 
cian, although the reasons were not always stated in the 
medical record. The baseline characteristics of the two 
groups were compared and P-values calculated using the 
Student’s t-test. 
Response at the end of treatment was categorized 
as follows: (1) cured: resolution of all attributable symp- 
toms, signs, and radiologic abnormalities due to aspergillo- 
sis present at baseline; (2) improved: major improvement 
in all attributable baseline features; (3) unchanged: minor 
or no improvement in abnormalities due to aspergillosis; 
and (4) failure: deterioration in attributable clinical and 
radiologic abnormalities or resulting in death due to 
aspergillosis. 
Mortality was assessed at completion of therapy for 
aspergillosis. Safety assessments were based on the 
known adverse event profiles of amphotericin B and 
itraconazole.8~17 
RESULTS 
The baseline characteristics of 21 patients with invasive 
aspergillosis are shown in Table 1. The two groups had 
comparable baseline characteristics, including mean 
APACHE III score at diagnosis (47 in the combination 
therapy group vs. 51 in the amphotericin B group). All 
patients received amphotericin B (1 mg/kg/d) and/or itra- 
conazole (400 mg/d) (capsules or suspension, depend- 
ing on the clinical situation). 
Table 2 compares the response to therapy for the 
two groups of patients. Nine (82%) of 11 patients who 
received amphotericin B and itraconazole were cured or 
improved versus 5 (50%) of 10 patients who received 
amphotericin B alone (P = 0.12). Two (18%) patients 
failed therapy or had unchanged clinical and radiologic 
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Table 1. Baseline Characteristics of 21 Patients with Invasive Aspergillosis 
Treatment Group 
Characteristic Amphotericin 8 and ltraconazole Amphotericin 6 
Patients (n) 11 10 
Mean age (y) 41.2 48.7 
Male 7 6 
Hematologic malignancy 7 9 
Solid tumor 4 1 
Immunosuppressive therapy* 6 5 
Neutropenic at diagnosis (G00/mm3) 1 2 
Allogeneic bone marrow transplant recipient 4 3 
HIV disease 2 0 
Mean APACHE III score at diagnosis 47 51 
Aspergillosis diagnosis: 
Definite/probable a/3 a/2 
Pulmonary 9 7 
Sinus 1 3 
Other 1 0 
Mean treatment duration (d) 34/95 33 
*Defined as steroid treatment, antithymocyte globulin and/or cyclosporine prior to diagnosis of invasive aspergillosis. 
P-Value 
0.28 
>0.50 
0.33 
0.15 
>0.50 
0.47 
>0.50 
0.15 
>0.50 
>0.50 
conditions in the amphotericin B and itraconazole group 
compared with 5 (50%) patients in the amphotericin B 
group. Mortality in the combination group was 27% 
(3 patients) versus 50% (5 patients) in the amphotericin 
B group. 
Among patients with invasive pulmonary aspergillo- 
sis, six of eight patients in the amphotericin B and itra- 
conazole group were cured or improved versus four of 
seven who were cured or improved in the ampbotericin 
B group. 
No patients who received combination therapy 
required drug discontinuation due to side effects. How- 
ever, three patients who received amphotericin B and 
itraconazole had mild elevations of total bilirubin, and 
two additional patients had a rise in alkaline phosphatase. 
No changes in total bilirubin or alkaline phosphatase 
were noted in patients treated with amphotericin B alone. 
The incidence and severity of renal insufficiency was sim- 
ilar for both groups (two patients in each group had 
reversible rises in serum creatinine to 2.4 mg/dL from 
normal baseline values). 
CONCLUSION 
Itraconazole and amphotericin B used in combination 
resulted in higher rates of cure or improvement than did 
amphotericin B alone, among comparable groups of 
patients with invasive aspergillosis. Furthermore, the com- 
bination of itraconazole and amphotericin B was not clin- 
ically antagonistic, in contrast to the finding of antagonism 
in some animal studies,‘* Although the improvement in 
outcome among patients who received itraconazole and 
amphotericin B was not statistically significant, this retro- 
spective study suggests that the addition of itraconazole 
to amphotericin B in the management of aspergillosis 
may be a useful therapeutic measure. A power analysis 
suggests that it would be necessary to include twice as 
many patients in each arm, at the same distribution, to 
achieve statistical significance. 
In this series, most patients who received combina- 
tion therapy (10 of 11 patients) completed therapy with 
itraconazole alone. Despite the apparent “monotherapy” 
of this treatment, patients who receive itraconazole 
Table 2. Outcome and Mortality among Patients Receiving Amphotericin B 
with ltraconazole or Amphotericin B Alone for Invasive Aspergillosis 
Treatment Group 
Amphotericin B and ltraconazole 
Outcome n= I? (%) 
Cured 3 (27) 
Improved 6 (54) 
Unchanged 
2ia) Failed 
Death* 3 (27) 
Death due to aspergillosis 2 (18) 
Death due to underlying disease 1 (9) 
Alive at end of therapy 7 (63) 
*Defined as mortality during treatment; IO of 11 patients received combinatron therapy. 
Amphotericin B 
n=lO(%) 
2 (20) 
3 (30) 
’ (10) 
4 (40) 
5 (50) 
4 (40) 
1 (10) 
5 (50) 
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following amphotericin B are, in reality, receiving 
combination treatment for several days to weeks. This 
supposition is based on the pharmacodynamics of 
amphotericin B, levels of which may be detected 3 to 6 
weeks after the last dose,“@ an effect that may be pro- 
longed, depending on the total dose given and degree of 
renal insufficiency. The “effective” continuation of com- 
bination therapy results in treatment with both drugs, 
not with itraconazole alone. 
Potential flaws of this study are similar to those of 
most retrospective studies: patients were not randomized 
and treatment was unblinded. The choice of therapy for 
each patient was based on physician preference, best 
judgment, and ability of patients to take oral medications 
or discontinue concomitant medications contraindicated 
with itraconazole use. Unfortunately, the number of 
patients was not sufficient to detect statistical signifi- 
cance or to assess the true therapeutic benefit of the 
combination regimen. 
In earlier animal models, the evidence that suggested 
mycologic antagonism from combinations of ampho- 
tericin B and itraconazole was based only on a mortality 
assessment.‘* In the uncontrolled environment of the 
clinical setting, a similar assessment is more difficult to 
make, as many other factors may have obscured antifun- 
gal antagonism. It is therefore possible that antagonism 
due to combined polyene-triazole therapy may have been 
missed. 
The data presented in this study suggest that the addi- 
tion of itraconazole to amphotericin B was well tolerated 
and produces no obvious mycologic antagonism with 
amphotericin B. A prospective, randomized, controlled 
study is needed to determine the true benefit of com- 
bined itraconazole and amphotericin B in the treatment 
of invasive aspergillosis. 
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